MENU
+Compare
DRUG
Stock ticker: NASDAQ
AS OF
Apr 1, 04:59 PM (EDT)
Price
$36.11
Change
+$0.04 (+0.11%)
Capitalization
256.83M

DRUG Bright Minds Biosciences Forecast, Technical & Fundamental Analysis

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain... Show more

DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for DRUG with price predictions
Mar 31, 2025

DRUG's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for DRUG turned positive on March 13, 2025. Looking at past instances where DRUG's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DRUG advanced for three days, in of 131 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 27 cases where DRUG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DRUG as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DRUG moved below its 50-day moving average on March 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DRUG crossed bearishly below the 50-day moving average on February 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRUG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DRUG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.293) is normal, around the industry mean (13.677). P/E Ratio (0.000) is within average values for comparable stocks, (64.969). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.870). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (255.565).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRUG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
19 Vestry Street
Phone
+1 647 865-8622
Employees
N/A
Web
https://www.brightmindsbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NMMEX15.21N/A
N/A
Northern Active M Emerging Market Equity
OEGYX29.32N/A
N/A
Invesco Discovery Mid Cap Growth Y
TSMNX13.78N/A
N/A
Nuveen Quant Small/Mid Cap Eq I
FEMYX11.33N/A
N/A
Fidelity Series Sustainable Emerg Mkts
QTERX10.52-0.02
-0.19%
AQR Emerging Multi-Style II R6

DRUG and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with PHMMF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then PHMMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
-1.18%
PHMMF - DRUG
42%
Loosely correlated
N/A
IVA - DRUG
39%
Loosely correlated
+1.19%
PSTV - DRUG
33%
Poorly correlated
-18.09%
ATYR - DRUG
32%
Poorly correlated
-3.51%
MNMD - DRUG
31%
Poorly correlated
-5.49%
More